Endra Life Sciences Inc (NDRA) Stock Price, Quote & News

Company Profile

ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source comprising radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 734 335 0468

Website: endrainc.com

Address:

3600 Green Court, Suite 350, Ann Arbor, United States

BeanBuyerB Dec. 25 at 9:32 AM

$NDRA Decision quality at the top will shape trajectory, while valuation increasingly tracks execution consistency. The upside case requires evidence, not projection.

0 · Reply

MadMaverick Dec. 17 at 8:25 PM

🚨 $NDRA is rewriting the MedTech playbook. By disrupting the $28B liver diagnostic market with TAEUS technology, they deliver MRI-grade insights for less than $200 while targeting the global MASLD/MASH crisis. Recent Win: Feasibility studies just confirmed high accuracy vs. the MRI gold standard. The Catalyst: 🔹Pivotal FDA study and De Novo filing in 2026. 🔹Innovative Treasury Strategy: Staking HYPE tokens to fund ops with non-dilutive yield. A high-risk, high-reward pivot! Get our Research on the company https://youtu.be/eDjkgwRprWQ Communicated Disclaimer - https://chartingdaily.com/liver-health-breakthrough

0 · Reply

The1Albatross Dec. 15 at 3:42 PM

$NDRA Vetting in demand, nice analyst PT and pipeline progressing.

1 · Reply

m1ster_leboeuf Dec. 12 at 12:42 PM

$NDRA Just go to zero.. embarrassing.

1 · Reply

MadMaverick Dec. 10 at 5:01 PM

And there we go! $NDRA with a strong upgrade , hitting $8+ yesterday! $NDRA Given $30 Price Target

1 · Reply

WallStreetBuyDip Dec. 10 at 5:23 AM

$NDRA Massive volume spike with 685.9K shares traded, well above the 2x average volume. Price has been volatile, ranging from $3.09 to $8.84 recently. Current price at $5.80. Waiting for a lower H% before considering a position.

0 · Reply

Mig77075 Dec. 10 at 1:05 AM

$NDRA look at the market cap..If the new device is much lower in cost than the MRI, thiis company should blow up to the stratosphere and higher! Just saying.

0 · Reply

DaBullRunner Dec. 10 at 12:15 AM

$ENVB if you missed this call 🚨ENSC🚨adding this before the masses arrive 🚨 $GWAB $GWAV $NDRA $LGHL what a day

0 · Reply

Mig77075 Dec. 9 at 11:12 PM

$NDRA Just sayin. Also look at $GPUS

0 · Reply

jacksparo Dec. 9 at 10:44 PM

$NDRA Team did you see this one?!! It got to 8.20 AH My Telegram you know what I am talking about!!! Enjoy your night!

1 · Reply

ENDRA's TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial Use

Nov 20, 2025, 8:00 AM EST - 4 weeks ago

ENDRA Feasibility Study Demonstrates TAEUS® Accurately Quantifies Liver Fat Fraction, a Key MASLD/MASH Biomarker

Nov 17, 2025, 8:00 AM EST - 5 weeks ago

ENDRA Life Sciences Recaps Major Milestones and New Strategic Initiatives, Announces Third Quarter 2025 Financial Results

Nov 13, 2025, 8:00 AM EST - 5 weeks ago

ENDRA Life Sciences Commences Staking of HYPE Digital Asset Holdings, Reinforcing Long-Term Strategy with Anchorage Digital and ARCA

Oct 23, 2025, 8:00 AM EDT - 2 months ago

ENDRA Life Sciences Closes Up to $14.4 Million Private Placement and Launches Crypto Treasury Strategy with $3 Million in Initial HYPE Token Holdings

Oct 13, 2025, 8:00 AM EDT - 2 months ago

ENDRA Life Sciences Announces At-Market Private Placement of Up to $14.4 Million to Launch Digital Asset Treasury Strategy Managed by Leading Crypto Asset Manager Arca

Aug 14, 2025, 4:05 PM EDT - 4 months ago

ENDRA Life Sciences Provides a Business Update and Reports Second Quarter 2025 Financial Results

Jun 16, 2025, 8:00 AM EDT - 6 months ago

ENDRA's Ongoing Multisite Pilot Study Reveals Important Enhancements to Boost TAEUS Liver Accuracy and Repeatability Against MRI Gold Standard

May 15, 2025, 4:05 PM EDT - 7 months ago

ENDRA Life Sciences Provides a Business Update and Reports First Quarter 2025 Financial Results

Mar 31, 2025, 8:05 AM EDT - 9 months ago

ENDRA Life Sciences Announces Enhanced Strategy to Enable the Early Detection and Management of Metabolic Diseases Facilitated by Emerging GLP-1 Therapies

Mar 31, 2025, 8:00 AM EDT - 9 months ago

ENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business Update

Nov 22, 2024, 8:00 AM EST - 1 year ago

ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

Nov 15, 2024, 9:24 AM EST - 1 year ago

ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update

Nov 12, 2024, 8:00 AM EST - 1 year ago

Study Highlighting ENDRA Life Sciences' TAEUS Technology in Patients with High BMI to be Presented at AASLD's The Liver Meeting® 2024

Nov 6, 2024, 8:00 AM EST - 1 year ago

ENDRA Life Sciences Further Strengthens TAEUS® Platform Intellectual Property with Issuance of 17th European Patent

Oct 22, 2024, 8:00 AM EDT - 1 year ago

ENDRA Life Sciences Activates TAEUS System to Initiate Clinical Study at LMU University Hospital in Germany

Aug 30, 2024, 8:54 AM EDT - 1 year ago

Data I/O And 2 Other Stocks Under $5 Executives Are Buying

DAIO

Aug 28, 2024, 4:17 PM EDT - 1 year ago

ENDRA Life Sciences Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirements

Aug 22, 2024, 5:54 PM EDT - 1 year ago

ENDRA Life Sciences Inc. (NDRA) Q2 2024 Earnings Call Transcript

Aug 22, 2024, 4:14 PM EDT - 1 year ago

ENDRA Life Sciences Reports Second Quarter 2024 Financial Results and Provides a Business Update

Aug 16, 2024, 8:00 AM EDT - 1 year ago

ENDRA Life Sciences Announces Reverse Stock Split

Aug 13, 2024, 4:05 PM EDT - 1 year ago

ENDRA Life Sciences Reschedules Second Quarter Conference Call to August 22, 2024

Aug 13, 2024, 8:00 AM EDT - 1 year ago

ENDRA Life Sciences Announces Leadership Changes

Aug 7, 2024, 8:00 AM EDT - 1 year ago

ENDRA Life Sciences to Report Second Quarter 2024 Financial Results on August 14

Jun 4, 2024, 9:21 AM EDT - 1 year ago

ENDRA Life Sciences Announces Pricing of $8.0 Million Public Offering

Jun 4, 2024, 9:06 AM EDT - 1 year ago

AM Best to Host Webinar on Engaging Defense Counsel Pre-Lawsuit

May 20, 2024, 8:00 AM EDT - 1 year ago

ENDRA Provides Update Following In-person Meeting with FDA

May 14, 2024, 8:30 PM EDT - 1 year ago

ENDRA Life Sciences Inc. (NDRA) Q1 2024 Earnings Call Transcript

May 14, 2024, 4:05 PM EDT - 1 year ago

ENDRA Life Sciences Reports First Quarter 2024 Financial Results and Provides a Business Update

May 7, 2024, 8:00 AM EDT - 1 year ago

ENDRA Life Sciences to Report First Quarter 2024 Financial Results on May 14, 2024

May 2, 2024, 8:00 AM EDT - 1 year ago

ENDRA Life Sciences Strengthens Intellectual Property with Issuance of Five New International Patents

Mar 28, 2024, 9:10 PM EDT - 1 year ago

ENDRA Life Sciences Inc. (NDRA) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 4:05 PM EDT - 1 year ago

ENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 21, 2024, 8:00 AM EDT - 1 year ago

ENDRA Life Sciences to Report Fourth Quarter 2023 Financial Results on March 28, 2024

Feb 27, 2024, 8:00 AM EST - 1 year ago

ENDRA Life Sciences Installs First TAEUS System in the UK

Feb 21, 2024, 8:00 AM EST - 2 years ago

New ICD-10-CM Code by the World Health Organization Paves the Way for Improved NAFLD Diagnostics Including ENDRA Life Sciences' TAEUS System

Feb 14, 2024, 8:30 AM EST - 2 years ago

ENDRA Life Sciences Bolsters TAEUS® System Intellectual Property with New Patents in U.S., China and Europe

Nov 29, 2023, 8:00 AM EST - 2 years ago

ENDRA Life Sciences Secures 39th U.S. Patent for TAEUS® System Technology

Nov 27, 2023, 8:00 AM EST - 2 years ago

ENDRA Life Sciences to Participate in The Benchmark Company's 12th Annual Discovery One-on-One Investor Conference

Nov 14, 2023, 10:14 PM EST - 2 years ago

ENDRA Life Sciences Inc. (NDRA) Q3 2023 Earnings Call Transcript

Nov 14, 2023, 4:05 PM EST - 2 years ago

ENDRA Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 8, 2023, 8:00 AM EST - 2 years ago

ENDRA Life Sciences Achieves Intellectual Property Milestone with Issuance of Three New Patents

Nov 7, 2023, 4:05 PM EST - 2 years ago

ENDRA Life Sciences to Report Third Quarter 2023 Financial Results on November 14, 2023

Nov 6, 2023, 8:00 AM EST - 2 years ago

ENDRA to Host Multidisciplinary Clinical Discussion on Managing Liver Disease During AASLD's The Liver Meeting® 2023

Sep 7, 2023, 8:00 AM EDT - 2 years ago

Abstract for ENDRA Life Sciences' TAEUS System Accepted for Presentation at EASL Steatotic Liver Disease Summit 2023

Aug 30, 2023, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences' TAEUS De Novo Submission Advances to Next Stage of Review with FDA

Aug 23, 2023, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences Expands Intellectual Property with Issuance of U.S. and European Patents

Aug 14, 2023, 9:44 PM EDT - 2 years ago

ENDRA Life Sciences Inc. (NDRA) Q2 2023 Earnings Call Transcript

Aug 14, 2023, 4:05 PM EDT - 2 years ago

ENDRA Life Sciences Reports Second Quarter 2023 Financial Results and Provides a Business Update

Aug 14, 2023, 1:30 PM EDT - 2 years ago

ENDRA Life Sciences Submits De Novo Request for its TAEUS® System Liver Fat Application to the U.S. FDA

BeanBuyerB Dec. 25 at 9:32 AM

$NDRA Decision quality at the top will shape trajectory, while valuation increasingly tracks execution consistency. The upside case requires evidence, not projection.

0 · Reply

MadMaverick Dec. 17 at 8:25 PM

0 · Reply

The1Albatross Dec. 15 at 3:42 PM

$NDRA Vetting in demand, nice analyst PT and pipeline progressing.

1 · Reply

m1ster_leboeuf Dec. 12 at 12:42 PM

$NDRA Just go to zero.. embarrassing.

1 · Reply

MadMaverick Dec. 10 at 5:01 PM

And there we go! $NDRA with a strong upgrade , hitting $8+ yesterday! $NDRA Given $30 Price Target

1 · Reply

WallStreetBuyDip Dec. 10 at 5:23 AM

0 · Reply

Mig77075 Dec. 10 at 1:05 AM

$NDRA look at the market cap..If the new device is much lower in cost than the MRI, thiis company should blow up to the stratosphere and higher! Just saying.

0 · Reply

DaBullRunner Dec. 10 at 12:15 AM

$ENVB if you missed this call 🚨ENSC🚨adding this before the masses arrive 🚨 $GWAB $GWAV $NDRA $LGHL what a day

0 · Reply

Mig77075 Dec. 9 at 11:12 PM

$NDRA Just sayin. Also look at $GPUS

0 · Reply

jacksparo Dec. 9 at 10:44 PM

$NDRA Team did you see this one?!! It got to 8.20 AH My Telegram you know what I am talking about!!! Enjoy your night!

1 · Reply

SeekingAlphalpha Dec. 9 at 10:44 PM

$NDRA and done

0 · Reply

cannacollector Dec. 9 at 10:39 PM

$NDRA 🤩

0 · Reply

jdlman Dec. 9 at 10:32 PM

$NDRA oh yeaema strong path

0 · Reply

Jubilantbeatbox Dec. 9 at 10:30 PM

$NDRA starting to run $AFJK $TGL $CETX

0 · Reply

DylanGFM Dec. 9 at 10:26 PM

$NDRA volume not increasing enough yet

0 · Reply

b4udie Dec. 9 at 10:26 PM

$NDRA something is up, the AH volume is 5 times today volume.

0 · Reply

MRWILL_ Dec. 9 at 10:24 PM

$SUGP $NDRA $SUGP $LGHL

0 · Reply

DylanGFM Dec. 9 at 10:23 PM

$NDRA they've been happening all day on low volume I'm tired of missing them

0 · Reply

DaBullRunner Dec. 9 at 10:23 PM

$NDRA there it goes .. 🚨KITT🚨smart money adding here as this is heavily lagging behind its peers RR and SERV…. Sooner or later this will pay me HUGE I’m telling you I’m even willing to put some of my COIN TSLA profits into KITT👇💰💰💰

0 · Reply

cannacollector Dec. 9 at 10:23 PM

$NDRA 🔥

0 · Reply

DylanGFM Dec. 9 at 10:23 PM

$NDRA is there no one seeing this?!

1 · Reply

b4udie Dec. 9 at 10:22 PM

$NDRA any news?

0 · Reply

Market Cap	3.84M
Revenue (ttm)	0.00
Net Income (ttm)	-11.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	5,600
Avg Vol	90,664
Day's Range	N/A - N/A
Shares Out	753,000.00
Stochastic %K	37%
Beta	-0.33
Analysts	Sell
Price Target	$30.00